Table 1 Correlation between specific fusion transcripts and clinical features of pro-B-ALL
Clinical features | KMT2A rearrangement (%) | BCR-ABL1 (%) | ETV6-RUNX1 (%) | Pro-B without fusion (%) | P |
|---|---|---|---|---|---|
Gender | |||||
 Male | 18 (56) | 4 (100) | 0 (0) | 47 (58) | 0.074 |
 Female | 14 (44) | 0 (0) | 3 (100) | 34 (42) | |
Age (years) | |||||
 < 1 | 9 (28) | 0 (0) | 0 (0) | 2 (2) | < 0.001 |
 1–10 | 20 (63) | 2 (50) | 2 (67) | 63 (78) | |
 ≥ 10 | 3 (9) | 2 (50) | 1 (33) | 16 (20) | |
WBC | |||||
 < 50 × 109/L | 16 (50) | 4 (100) | 3 (100) | 60 (74) | 0.027 |
 ≥ 50 × 109/L | 16 (50) | 0 (0) | 0 (0) | 21 (26) | |
Prednisone response | |||||
 Good | 29 (91) | 4 (100) | 3 (100) | 75 (93) | 0.835 |
 Poor | 3 (9) | 0 (0) | 0 (0) | 6 (7) | |
MRD at day 33 | |||||
 < 0.01% | 10 (37) | 1 (25) | 0 (0) | 15 (24) | 0.747 |
 0.01–1% | 14 (52) | 2 (50) | 2 (100) | 35 (56) | |
 ≥ 1% | 3 (11) | 1 (25) | 0 (0) | 12 (19) | |
MRD at day 78 | |||||
 < 0.1% | 22 (81) | 3 (100) | 2 (100) | 51 (86) | 0.789 |
 ≥ 0.1% | 5 (19) | 0 (0) | 0 (0) | 8 (14) | |